United Biotech Private Limited

United Biotech Private Limited (UBPL) is a privately held pharmaceutical company established on January 31, 1997, in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U24239DL1997PTC084814. UBPL specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. As of December 20, 2025, the company reported an authorized capital of ₹5.00 crore and a paid-up capital of ₹4.54 crore.

The registered office is located at E-142, Saket, New Delhi, Delhi, 110017, India. UBPL employs approximately 831 professionals, reflecting its significant presence in the pharmaceutical manufacturing sector. The company's website, administration@unitedbiotechindia.com, serves as a point of contact for business inquiries.

UBPL operates a state-of-the-art manufacturing facility in New Delhi, India. The plant is certified for WHO-cGMP and ISO 9001:2008, ensuring adherence to international quality standards. (about.me) This facility specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to both domestic and international markets.

The leadership team at UBPL comprises:

• Rajiv Kumar: Whole-Time Director since January 31, 1997.
• Sanjeev Kumar: Whole-Time Director since April 2, 2007.
• Ashwani Kumar: Whole-Time Director since December 7, 2013.

These directors play pivotal roles in steering the company's strategic direction and operations.

UBPL has made significant strides in regulated markets, obtaining approvals from various international regulatory bodies. The company has secured WHO prequalification for several of its products, facilitating access to markets in Africa, Latin America, and Southeast Asia. Additionally, UBPL holds EU GMP certificates, enabling it to export to European Union countries. The company's adherence to international standards underscores its commitment to quality and regulatory compliance.

UBPL has strategically expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The WHO prequalification of its products has been instrumental in this expansion, allowing the company to meet the stringent requirements of these regions. This strategic focus has enhanced UBPL's global footprint and market diversification.

UBPL's geographic strategy emphasizes diversification, reducing reliance on any single market. The company's expansion into emerging markets, coupled with its presence in regulated markets, reflects a balanced approach to global market penetration. This strategy mitigates concentration risk and positions UBPL for sustained growth.

UBPL has registered its manufacturing facility with the U.S. Food and Drug Administration (FDA), allowing it to export pharmaceutical products to the United States. The company has filed multiple Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs), demonstrating its commitment to meeting FDA standards. UBPL's facilities have undergone FDA inspections, resulting in favorable outcomes, which attest to the company's adherence to stringent quality and regulatory requirements.

UBPL's manufacturing facility holds WHO Good Manufacturing Practice (GMP) certification, ensuring compliance with international quality standards. The company also possesses EU GMP certificates, facilitating exports to European Union markets. These certifications reflect UBPL's dedication to maintaining high-quality manufacturing processes.

UBPL operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds the necessary manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. UBPL also possesses export No Objection Certificates (NOCs), authorizing it to export pharmaceutical products to various international markets.

UBPL has maintained a clean regulatory record, with no reported Form 483 observations, warning letters, or import alerts from regulatory bodies such as the FDA. This track record underscores the company's commitment to quality and regulatory compliance.

UBPL operates in a competitive landscape, with several pharmaceutical companies offering similar products in overlapping therapeutic categories. While specific market share data is not publicly disclosed, UBPL's focus on high-quality manufacturing and regulatory compliance positions it favorably in the market. The company's strategic expansion into emerging markets further enhances its competitive edge.

UBPL's key differentiators include its state-of-the-art manufacturing facility certified for WHO-cGMP and ISO 9001:2008, a diverse product portfolio across multiple therapeutic categories, and a strong presence in both regulated and emerging markets. These factors collectively contribute to the company's competitive advantage in the pharmaceutical industry.

UBPL's current strategic direction focuses on expanding its presence in both regulated and emerging markets, leveraging its manufacturing capabilities and regulatory certifications. The company's future outlook includes further diversification of its product portfolio and geographic reach, aiming for sustained growth and leadership in the global pharmaceutical sector.

UBPL has demonstrated a strong track record in pharmaceutical manufacturing, with consistent export volumes and adherence to international quality standards. The company's reliability is evidenced by its certifications and favorable regulatory inspections. UBPL's commitment to quality and compliance makes it a dependable supplier in the pharmaceutical industry.

Importers should verify the following certifications when considering UBPL as a supplier:

• FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.
• WHO GMP Certification: Ensure the manufacturing facility holds WHO Good Manufacturing Practice certification.
• EU GMP Certification: Verify the presence of EU Good Manufacturing Practice certificates.
• ISO 9001:2008 Certification: Check for ISO 9001:2008 certification, indicating adherence to quality management standards.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting UBPL directly.

When conducting due diligence on UBPL, consider the following steps:

• Verify Regulatory Certifications: Confirm the validity of FDA, WHO GMP, EU GMP, and ISO 9001:2008 certifications.
• Review Financial Statements: Examine the company's financial health by reviewing recent balance sheets and profit and loss statements.
• Assess Manufacturing Capabilities: Evaluate the capacity and capabilities of UBPL's manufacturing facility.
• Check Regulatory Compliance History: Investigate any past regulatory issues or violations.
• Evaluate Product Portfolio: Assess the diversity and quality of UBPL's product offerings.

Red flags to watch for include expired or invalid certifications, unresolved regulatory issues, and inconsistent financial performance. Recommended pre-order checks involve obtaining and verifying copies of all relevant certifications and financial documents.